LUMOS DIAGNOSTICS HOLDINGS LIMITED (LDX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

LDX

LDX - LUMOS DIAGNOSTICS HOLDINGS LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.25
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.10

29 Jul
2026

0.000

OPEN

$0.10

0.000

HIGH

$0.11

339,490

LOW

$0.10

TARGET
$0.25 150.0% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
LDX: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 1.6 - 1.2 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx19.1 M
Book Value Per Share xxxxxxxxxxxxxxx1.3
Net Operating Cash Flow xxxxxxxxxxxxxxx-14.4 M
Net Profit Margin xxxxxxxxxxxxxxx-57.93 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-110.69 %
Return on Invested Capital xxxxxxxxxxxxxxx-55.81 %
Return on Assets xxxxxxxxxxxxxxx-30.83 %
Return on Equity xxxxxxxxxxxxxxx-110.69 %
Return on Total Capital xxxxxxxxxxxxxxx-58.27 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-14.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx2 M
Long Term Debt xxxxxxxxxxxxxxx9 M
Total Debt xxxxxxxxxxxxxxx11 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxxxxx2.15

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.1 M
Capex % of Sales xxxxxxxxxxxxxxx0.43 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx8 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

28/07/2026

1

Buy

$0.25

150.00%

Lumos Diagnostics received US$7m in the June quarter, triple the prior quarter and reflecting the US$5m milestone payment from PHASE Scientific following the CLIA waiver approval.

This drove operating cash flow to over US$2.7m. The company reports that 60 days after commercial launch the FebriDx roll-out is running ahead of expectations.

The upcoming US flu season should mean a heightened level of FebriDx orders in the September and December quarters. Bell Potter highlights the key catalysts remain utilisation, in the lead up to the flu season, and contract wins in urgent care. Buy rating maintained. Target is 25c.

FORECAST
Bell Potter forecasts a full year FY26 EPS of minus -1.20 cents.
Bell Potter forecasts a full year FY27 EPS of minus -1.00 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

LDX STOCK CHART

FNArena News on LDX

1
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
2
Australian Broker Call *Extra* Edition – Mar 21, 2023

Mar 21 2023 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Sep 06, 2022

Sep 06 2022 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 10, 2022

Aug 10 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jul 18, 2022

Jul 18 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
2
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
3
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
4
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
5
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
6
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
7
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
8
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
9
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
10
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest